Percutaneous Vessel Closure Devices Market

Percutaneous Vessel Closure Devices Market Forecast and Outlook 2026 to 2036

The global percutaneous vessel closure devices market is projected to total USD 4.34 billion in 2026, advancing to USD 9.27 billion by 2036, progressing at a 7.9% CAGR. This expansion is central to the evolution of minimally invasive vascular procedures, where efficient hemostasis directly enhances patient recovery and procedural workflow. Suture-based closure devices lead the segment, offering secure femoral artery closure common in interventional cardiology.

Key Takeaways from the Percutaneous Vessel Closure Devices Market

• Market Value for 2026: USD 4.34 Billion
• Market Value for 2036: USD 9.27 Billion
• Forecast CAGR 2026 to 2036: 7.9%
• Leading Device Type Segment (2026): Suture-Based Closure Devices (32.3%)
• Leading Application Segment (2026): Interventional Cardiology (36.1%)
• Leading End User Segment (2026): Hospitals & Cath Labs (45.6%)
• Key Growth Countries: India (10.7% CAGR), Brazil (10.3% CAGR), China (9.9% CAGR), USA (6.8% CAGR), Germany (6.7% CAGR), France (6.6% CAGR), UK (6.5% CAGR)
• Key Players: Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Haemonetics Corporation, Merit Medical

The rising volume of diagnostic and therapeutic catheterizations, alongside growing adoption of large-bore access for structural heart therapies, sustains robust demand. Hospitals and catheterization laboratories constitute the dominant end-user, driven by procedure volume and the need for rapid patient ambulation.

Accelerated growth in emerging economies reflects both improving access to interventional care and the establishment of new cardiac catheterization labs, integrating advanced closure technologies from the outset to optimize patient outcomes and department efficiency.

Percutaneous Vessel Closure Devices Market

Category

What Clinical and Economic Factors are propelling the Shift from Manual Compression?

The relentless growth in percutaneous coronary interventions and complex endovascular procedures mandates faster, more reliable femoral access site management to reduce lab turnover time and length of stay.

Manual compression, while low-cost, is labor-intensive and variable. The expansion of transcatheter structural heart therapies such as TAVR and TMVR requires closure of larger arteriotomies, a challenge beyond manual methods that drives adoption of advanced suture or hybrid devices.

The economic transition toward outpatient or short-stay interventional procedures creates a powerful incentive for devices that enable immediate hemostasis and early ambulation, improving patient satisfaction and hospital throughput while reducing vascular complication risks associated with prolonged bed rest.

Segmental Analysis

By Device Type, Which Technology Balances Secure Closure with Proven Track Record?

Suture-based closure devices command a leading 32.3% share. This segment’s prominence is built on its mechanism, which provides a true surgical suture closure of the arteriotomy, offering high strength and a low profile.

Its extensive long-term clinical data and reliability in both elective and complex cases have made it a preferred choice among many interventional cardiologists and radiologists. The ability to achieve rapid hemostasis even with larger sheath sizes supports its central role in modern cath labs.

By Application, Where is Procedural Volume Highest and Most Routine?

Interventional cardiology constitutes the primary application segment at 36.1%. The enormous global volume of percutaneous coronary interventions for coronary artery disease forms the bedrock of demand. The routine nature of femoral access in these procedures, combined with the clinical and economic benefits of rapid closure, ensures consistent, high-volume utilization of closure devices, making this the largest and most stable application driver.

By End User, Where is the Concentration of High-Volume Vascular Access Procedures?

Hospitals and catheterization labs hold a decisive 45.6% share. These facilities are the epicenters for diagnostic and interventional vascular procedures. The high daily procedure volume, coupled with the need for predictable outcomes to maintain efficient patient flow, makes investment in reliable closure technology a operational necessity. Their purchasing decisions are heavily influenced by physician preference, clinical evidence, and total cost-of-care considerations beyond just device price.

Which Dynamics will likely Influence the Market for Percutaneous Vessel Closure Devices?

Analysis of the Percutaneous Vessel Closure Devices Market by Key Countries

How do Procedure Volumes and Reimbursement Shape USA’s Percutaneous Vessel Closure Devices Market?

High PCI volumes support a 6.8% CAGR, strong reimbursement for closure devices, and rapid adoption of large-bore TAVR procedures. Physician preference for specific device types is a key market shaper. Growth is sustained by technological iterations of existing platforms and training programs that integrate device use into fellowship training, ensuring continued generational adoption.

What Drives Demand within Germany's Advanced Interventional Cardiology Sector?

Germany's 6.7% CAGR reflects a high standard of interventional care and early adoption of complex structural heart procedures. German clinicians value precision engineering and robust clinical data, favoring devices with proven outcomes in peer-reviewed literature. The market is characterized by methodical evaluation and a focus on reducing vascular access site complications.

Which Dynamics Underpin China's Rapid Expansion in Interventional Capabilities?

China's 9.9% CAGR is propelled by massive infrastructure development, with new catheterization labs opening across tier 2 and 3 cities. Rising domestic production of interventional devices and government drives to improve CVD treatment are expanding access. Growth involves training a new cohort of interventionalists on advanced closure techniques alongside basic procedures.

Why does India's Healthcare Infrastructure Growth Catalyze High Demand?

India's leading 10.7% CAGR is tied to the proliferation of private cardiac hospitals and cath labs. Rising PCI volumes and increasing patient expectations for quick recovery drive adoption. The market is sensitive to cost but shows strong uptake for devices that demonstrably reduce length of stay and complication rates, offering a clear return on investment.

How is Brazil's Focus on Cardiovascular Health Influencing Market Development?

Brazil's 10.3% CAGR is linked to a high burden of cardiovascular disease and expanding access to interventional therapy within both public and private systems. Growth is concentrated in urban centers where labs are investing in modern equipment. Adoption balances cost considerations with the need for reliable technologies suitable for varied patient anatomies.

What Characterizes France's Adoption within a Centralized Health System?

France's 6.6% CAGR operates within a hospital-centric system where procurement decisions are influenced by national health authority assessments. Adoption of new device types is evidence-based and relatively standardized across major university hospitals. High procedural volumes and ongoing upgrades drive steady demand to interventional suites.

How does the UK's NHS Procurement and Radial-First Trend Interact?

NHS procurement frameworks favoring cost-effective solutions and the strong national shift toward radial access for coronary interventions shape the UK’s 6.5% CAGR. This moderates growth in traditional femoral closure devices but stimulates interest in novel products for radial closure or for essential large-bore femoral access in structural heart programs.

Competitive Landscape of the Percutaneous Vessel Closure Devices Market

The competitive landscape is consolidated among a few global medtech leaders with strong portfolios in interventional medicine. Companies compete on device efficacy, ease-of-use, clinical data, and physician training support.

Success hinges on securing key opinion leader endorsements, demonstrating superior outcomes in terms of time to hemostasis and complication rates, and providing robust technical support. Innovation focuses on reducing device profile, simplifying deployment mechanisms, and expanding indications for use in challenging anatomies or larger arteriotomies.

Key Players in the Percutaneous Vessel Closure Devices Market

• Abbott Laboratories
• Terumo Corporation
• Cardinal Health Inc.
• Haemonetics Corporation
• Merit Medical
• Others

References

• American College of Cardiology. (2025). Expert Consensus Decision Pathway on Vascular Access and Closure for Coronary Procedures.
• European Association of Percutaneous Cardiovascular Interventions (EAPCI). (2024). Clinical consensus on the management of access site complications.
• Jolly, S. S., & Rao, S. V. (2023). Vascular Access and Closure for Coronary and Peripheral Procedures. Elsevier.
• Katzen, B. T., & MacLean, A. A. (2025). Complications of Diagnostic and Therapeutic Angiography: A Focus on Access Site Management. Journal of Vascular and Interventional Radiology.
• U.S. Food and Drug Administration. (2024). Class II Special Controls Guidance Document: Vascular Closure Devices.
• Wong, S. C., & Popma, J. J. (2025). Innovations in Large-Bore Access and Closure for Structural Heart Interventions. Circulation: Cardiovascular Interventions.